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INTRODUCTION
Highly Active Antiretroviral Therapy (HAART)
refers to a category of treatment regimen usually
comprising of 3 or more antiretroviral drugs that are
expected to reduce plasma viral levels below the
limits of detection (500 copies/mL). Most HAART
regimens include drugs from at least 2 of the 3
classes of antiretroviral therapeutic drugs referred to
as Nucleoside Reverse Transcriptase Inhibitor
(NRTI), Non-Nucleoside Reverse Transcriptase
Inhibitor (NNRTI), and Protease Inhibitors (PI) .
Potent combination regimens offer the greatest
likelihood of reducing the replication of Human
Immunodeficiency Virus (HIV); facilitating CD4 T
cell expansion and delaying progression into
Acquired Immune Deficiency Syndrome (AIDS) .
Although it is well established that treatment with
HAART can lead to CD4 cell gain, full immune
recovery is often incomplete .
Some Physicians tend to delay the use of HAART
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reduce the associated adverse effect, since it has been
observed that this does not increase the mortality rate
in HIV patients with good compliance . Mortality rate
increases if HAART is initiated below CD4 cell count
of 200. Also, non-adherent patients have higher
mortality rates than those who are adherent with
similar CD4 cell count. Above the CD4 cell count of
200, medication adherence is the critical determinant
of survival, and not the CD4 Cell count at which
HAART is begun. Treatment delay however, has been
found to cause impaired functional immune
reconstruction . It has been observed that after the
initiation of HAART, there is usually a rapid increase
in CD4 cell count, and on the other hand, there is an
early fall in the count after interrupting therapy .
HAART also has a positive effect on CD4 cell count
in children with HIV infection . These changes may
however be affected by the co-infection with
Tuberculosis, which has been shown by Salami et al
to be associated with a lower CD4 cell count.
Involuntary weight loss or wasting is one of the most
common manifestations of HIV infection. It can
occur at any stage of infection, regardless of HAART
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To determine the response on treatment-naïve HIV/AIDS patients to the Highly Active
Antiretroviral Therapy (HAART) in terms of CD4 Count and Weight gain over a period of 2½ years.
Patients with Acquired Immunodeficiency Syndrome (AIDS) were recruited under the Federal
Government Highly Active Antiretroviral Therapy (HAART) programme at the University of Ilorin Teaching
Hospital. The treatment regimen included Lamivudine, Starvudine and Nevirapine. The patients' responses
were evaluated with respect to CD4 count and weight over the period of treatment. The diagnosis of HIV/AIDS
was made on the basis of reactivity with two different ELISAreagents, and CD4 count was done with Dynal T4
Quant method. The weights (kg.) of the patients were taken at monthly visit.
The duration of treatment for the patients analysed ranged from 1 month to 14 months. Analysis of
CD4 count was possible in 105 patients. The mean post treatment CD4 count and weight were significantly
higher than the pre-treatment values (p < 0.001 and p < 1.01) respectively. There were significant positive
correlations (p < 0.05 and p < 0.001) between increases in CD4 count and weight respectively, and duration of
treatment. In eight (8) patients, CD4 Count reduced or remained the same in spite of treatment.
The HAART regime is associated with increase in CD4 Count and weight gain. While increases in
CD4 Count and weight correlated with duration of therapy, there was no correlation between CD4 Count
increase and weight gain.
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w eig ht d = 8 .6 9 + 0 .00 * cd 4d
R -Sq u are = 0.00
Fi gure 1: Reg ress ion of in cre ase in CD 4 (cd 4d ) cou nt
versus increas e in weig h t (wei ghtd) in H IV/ AI DS p atien ts o n
HAART.
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been observed to reduce the impact of HIV disease
on body weight, in addition to the direct effect on
appetite, body composition, and body fat
redistribution .
Studies have established the positive impact of
HAART especially in patients with serious weight
loss of greater than 10% . Other studies have
however shown that the weight gain of HIV patients
on HAART is primarily fat with no changes in lean
body mass . Changes in body weight and Body Mass
Index (BMI) have also been found not to correlate
with changes in CD4 or plasma HIV RNA. Patients
with good CD4 and RNA response to HAART were
as likely to experience increase in weight and BMI as
patients with lesser response to HAART . The aim
of this review is therefore to examine: i. the response
of HIV/AIDS patients to HAART in terms of CD4
Count and weight, ii. the relationship between
increases in CD4 Count and weight, and iii. any
correlation between increase in CD4 Count and
increase in weight.
The University of Ilorin Teaching Hospital is one of
the centres approved by the Federal Government for
its programme on the Highly Active Antiretroviral
Therapy (HAART) for HIV/AIDS patients. Patients
had pre- and post-test counseling and were recruited
from February, 2002 based on reactivity of sera with
two different ELISA methods. Each patient was then
examined clinically and weights were taken before
commencement of the antiretroviral therapy. The
CD4 Cell Count was determined using the Dynal T4
Quant by Dynal Biotech ASA, Oslo, Norway.
Patients were recruited if CD4 cell count was 200
cells/l and below with or without AIDS-defining
clinical features, if they had Stage III disease with
CD4 cell count less than 350 cell/l, or Stage IV
disease regardless of CD4 cell count values, in line
with Nigeria's Guideline on the Antiretroviral
therapy . Treatment was done with three drug
regimen comprising Starvudine, 40mg. twice daily,
Lamivudine 150mg. twice daily, and Nevirapine,
200mg. twice daily, all taken orally. While on
treatment, patients had their CD4 Cell Count and
body weight among other parameters, monitored and
recorded at three monthly intervals. Prophylactic
antibiotics were not offered to the patients except
those with evidence of bacterial infections.
Analysis of patients' responses in terms of increase
or otherwise of CD4 Cell Count and body weight was
carried out in 185 patients two years after
commencement of the programme. The pretreatment
CD4 Count and weight were compared to those at the
point of analysis using the Students' t test while the
association between outcome measurements and










Comparison between Pre-Treatment and
Post-Treatment CD4 Cell Count and Weight
Correlation of Increase in CD4 Cell Count
and Weight with Duration ofTreatment
Patients were recruited at different times during the
treatment period. One hundred and eighty-five
patients, 91 male and 94 females aged 15 to 66 years,
were analysed at the end of two years of the HAART
programme. Due to the combination of patients
defaulting and financial incapacity, only 105 and 149
patients respectively had pre and post treatment CD4
Count and weight recorded along with period of
therapy. The period of treatment ranged from 1 to 14
months with a mean of 5 months.
The mean pre-treatment and post-treatment CD4
Counts were 218±133 and 370±180 cells/cu. mm.
respectively. The difference is statistically significant
(p = 0.000). The mean pre-treatment and post-
treatment weights were 52.1±10.6 and 59±10.5 kg.
respectively, and the difference was statistically
significant (p = 0.000) as shown in Table 1. There was
a significant positive correlation between duration of
treatment and increase in CD4 Count (r = 0.24, p =
0.013). There was a significant positive correlation
between the increase in weight and duration of
treatment (r = 0.458, p = 0.000), see Table 2. There
was no correlation between increase in CD4 cell
count and increase in weight (r = 0.0), see Table 2 and
Figure 1. In eight patients the CD4 Count remained









CD4 cell count/cu. mm. 218±133 370±180 105 0.000




Increase in CD4 count vs.
Treatment duration
0.24 0.013
Increase in Weight vs.
Treatment duration
0.458 0.000
Increase in weight vs. Increase
in CD4 cell count
0.00 0.997
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An index in the assessment of response to
antiretroviral therapy.
Only 8 patients experienced no improvement in CD4
count in spite of treatment. This could be due to
inadequate compliance to therapy, lack of response,
or very low pre-treatment CD4 count. The kind of diet
that these patients were able to afford is another factor
that should be considered.
In conclusion, this study has shown that the HAART
regimen conferred clinical improvement on patients
involved as the CD4 count and weight gain represent
good indices of response to therapy. Government and
NGOs should therefore proceed quickly with the
planned scaling up of the programme to make the
drugs available to more patients. The treatment of
infected children and prevention of mother to child
transmission should be given the same coverage as
for the HAART programme.
We wish to acknowledge the provision of the
Antiretroviral drugs by the Federal Government of
Nigeria at a subsidized price, which was affordable by
most patients. We are also grateful to Mrs. J.O.
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cell count.
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The treatment of HIV/AIDS has changed
considerably over the last 20 years as knowledge and
treatment options have increased. HAART was
introduced in 1996 in the industrialized countries and
its effects have been established in those countries .
Reports since 1999 in the United States of America
and the Netherlands have associated the use of
HAART with reduction in viral load and increase in
weight .
Not much work has been done in this part of the world
on this subject before now because the drugs were
very expensive and unaffordable to many patients
until recently when it was subsidized by the Federal
Government. Consequently, many more patients can
now afford to buy the drugs and this development has
made this study possible.
Analysis of the CD4 Cell Count was possible only on
105 patients because the CD4 Cell Count is even more
expensive than the drugs and some patients could not
afford to pay. The mean post-treatment CD4 Cell
Count was significantly higher than the pre-treatment
one and there was a significant positive correlation
between the post-treatment CD4 count and the
duration of treatment. This is in keeping with work
done in the industrialized countries state above .
Those with relatively lower CD4 Cell count pre-
therapy had a more dramatic increase in CD4 Count
than those with relatively higher CD4 Count pre-
therapy. This may be the reason for physicians'
preference for delaying the use of HAART until the
CD4 Cell Count falls to 200 cell/cu. mm. to avoid the
adverse effects of the drugs and moreso when such
delay does not increase the mortality rate . These
physicians however believe that mortality may
increase if treatment is started at CD4 Cell Count
below 200. In our study however, patients with CD4
Cell Counts below 200 cells/cu. mm. did well on the
HAART regimen, especially those who complied
well with the drugs. Antibiotics were given only to
patients with clinical, radiological, and laboratory
evidence of bacterial or mycobacterial infections,
since we have previously reported them to be
associated with relatively lower CD4 cell count and
reduced survival.
The mean post-treatment weight of those patients was
significantly higher than the pre-treatment weight,
and there was significant positive correlation between
the weight gain and duration of treatment. The weight
gain can be attributed to improvement in the clinical
condition of the patients, reduction in psychological
stress as well as a direct effect of the drug on the
appetite. However, it is interesting to note that, in line
with the finding of Verweel et al among children,
there was no correlation between increase in CD4 cell







may not be useful as surrogate for CD4 cell count or
314Nigerian Journal of Clinical Practice Dec. 2008, Vol.11(4) Antiretroviral Therapy On Cd4 Count Olatunji et al
7. Salami AK, Olatunji PO, Oluboyo PO.
8. Nemechek P, Polsky B, Gottlieb MS.
9. TangAM, Forrester J,Apiegelman D.
10. Zuniga-Roiz K, Hernandez-Daly AC, Torres
KJ.
Spectrum and prognostic significance of
opportunistic diseases in HIV/AIDS patients in
Ilorin, Nigeria. WAJM 2006; 25: 52-56.
Treatment guidelines for HIV associated
wasting. Mayo Clin Proc 2000; 75: 386-94.
Weight
loss and survival in HIV-positive patients in the
era of HAART. J Acquir immune defic. Syndr
2002; 31: 230-236.
HAART based on a PI sparing regimen,
reconstitutes muscle mass in HIV-infected
individuals with wasting syndrome but not in
those with moderate or no weight loss. XIV
International AIDS Conference, Barcelona,
2002AbstractWepe B5 993.
11. Pernerstofer-Schoen H, Schindler K,
Parschalk B.
12. Wanke C, Ostrowsky B, Gerrior J, Hestnes J.
13.
14. Salami AK, Olatunji PO, Oluboyo PO,
Akanbi II AA, Fawibe EA.
Beneficial effects of PI on body
composition and resting energy expenditure: a
comparison between HIV-infected and non-
infected patients.AIDS 1999; 13: 2389-96.
Effect of HAART on patients' weight and body
mass index. Int. ConfAIDS 1998; 12 : 1094.
Federal Ministry of Health. Guidelines for the
use of Antiretroviral (ARV) Drugs in Nigeria.
2005; page 31-31
Bacterial
pneumonia in the AIDS patients. WAJM 2006;
25: 1-5.
315Nigerian Journal of Clinical Practice Dec. 2008, Vol.11(4) Antiretroviral Therapy On Cd4 Count Olatunji et al
